Histone deacetylases and transcriptional therapy with their inhibitors Journal Article
| Author: | Pandolfi, P. P. |
| Article Title: | Histone deacetylases and transcriptional therapy with their inhibitors |
| Abstract: | Acute promyelocytic leukemia (APL) is characterized by the expansion of malignant myeloid cells blocked at the promyelocytic stage of hemopoietic development and is invariably associated with reciprocal chromosomal translocations involving the retinoic acid receptor alpha (RAR alpha) gene on chromosome 17. RAR alpha variably fuses to PML, PLZF, NPM, NuMA, and Stat5B genes (X genes/proteins). These translocations are balanced and reciprocal, thus leading to the generation of X-RAR alpha and RAR alpha -X fusion genes of which the products coexist in the APL blast. The invariable involvement in these translocations of RAR alpha, a prototypical transcription factor, makes APL a compelling example of aberrant transcriptional mechanisms in the etiopathogenesis of cancer. This paper focuses on the recent progress in defining the molecular mechanisms underlying APL pathogenesis and addresses how this new understanding has allowed the proposal and development of novel therapeutic strategies with compounds such as histone deacetylase inhibitors and inorganic arsenicals such as As2O3 which are currently being tested in murine leukemia models as well as in human APL patients. In particular, the crucial role played by the aberrant transcriptional activities of X-RAR alpha and RAR alpha -X fusion proteins in APL pathogenesis is discussed by reviewing the relevant therapeutic implications resulting from this analysis. |
| Keywords: | leukemia; mouse; histone; transgenic mice; acute promyelocytic leukemia; apl; deacetylase inhibitors; plzf-rar-alpha; as2o3; transcription therapy |
| Journal Title: | Cancer Chemotherapy and Pharmacology |
| Volume: | 48 |
| Issue: | 1 Suppl. |
| ISSN: | 0344-5704 |
| Publisher: | Springer |
| Date Published: | 2001-07-01 |
| Start Page: | S17 |
| End Page: | S19 |
| Language: | English |
| ACCESSION: | WOS:000171333000004 |
| DOI: | 10.1007/s002800100322 |
| PROVIDER: | wos |
| PUBMED: | 11587360 |
| Notes: | Presented at the 16th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium; 2000 Oct 27-28; Nagoya, Japan -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work